NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/21/2026 14:14
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization13.18 mln
Float4.16 mln
Earnings Date08/13/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
10.11
Highly suspicious
1-Year Forecast
23.00
Transformational upside
Relative Strength
78
/ 100
Strongly outperforming
Debt / Equity
0.54
Moderate leverage
ROE
-41.45
Deeply negative
Business Description
BioLineRx is an Israel-based company founded in 2003 that focuses on developing and selling treatments for cancer and rare diseases. Its leading product, APHEXDA, is being studied across multiple clinical trials for conditions including sickle cell disease, pancreatic cancer, and multiple myeloma. The company also has a non-surgical skin lesion removal product in development, BL-5010, which uses an acid-based solution applied through a pen-like device.
